Announcement selection Wuxi Biologics's first-half net profit increased by 35% to 37% compared with the same period last year; China Vanke: Wanyuyun H-share IPO application was approved by the China Securities Regulatory Commission


Source: futunn.com futunn.com

Key Topics in this News Article:

News Snapshot:

重磅公告精选 Selection of blockbuster announcements 1、 $药明生物(02269.HK)$ :预计上半年净利润同比增长35%至37% 1、 $Wuxi Biologics (02269.HK) $ It is estimated that net profit in the first half of the year will increase by 35% to 37% compared with the same period last year. 药明生物在港交所公告,集团预期与去年同期比较,截至2022年6月30日止六个月所录得的本公司收益将增长61%至63%;本公司利润及归属于本公司权益股东的利润相比于去年同期分别增长36%至38%和35%至37%。 Wuxi Biologics announced on the Hong Kong Stock Exchange that the Group expects the company's earnings for the six months ended June 30, 2022 to increase by 61% to 63% compared with the same period last year. The company's profits and profits attributable to the company's equity shareholders increased by 36% to 38% and 35% to 37% respectively compared with...